Following the new strategic vision of the CEO and his Team aiming on covering a large number of patients towards Europe with direct sales, Rivopharm is proudly announcing the acquisition of the 100% of the share capital of SANOSWISS UAB, Vilnius, Lithuania. With this acquisition Rivopharm, and its subsidiaries in the U.K. and Germany, is directly covering more than one third of the European Union population in the Generic, Branded Generic, OTC and Food Supplement markets. Thanks to the substantial legal support of Price Waterhouse Coopers Lithuania the transaction was successful and smooth. Both Rivopharm SA and the vendors have agreed not to disclose the financial details of the agreement.

‍